DK2371385T3 - Anvendelse af en PV2-immunogen sammensætning til mindskning af kliniske symptomer i grise - Google Patents
Anvendelse af en PV2-immunogen sammensætning til mindskning af kliniske symptomer i grise Download PDFInfo
- Publication number
- DK2371385T3 DK2371385T3 DK11164854.9T DK11164854T DK2371385T3 DK 2371385 T3 DK2371385 T3 DK 2371385T3 DK 11164854 T DK11164854 T DK 11164854T DK 2371385 T3 DK2371385 T3 DK 2371385T3
- Authority
- DK
- Denmark
- Prior art keywords
- pcv2
- group
- immunogenic composition
- pigs
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Claims (30)
1. Immunogen sammensætning i stand til at frembringe eller øge et immunrespons mod PCV2, og som omfatter rekombinant fremstillet PCV2-ORF2-protein til anvendelse i forebyggelse af lymfadenopati i kombination med ét eller flere af de følgende symptomer i grise: (1) interstitiel pneumoni med interlobulær ødem, (2) kutan bleghed eller ikterus, (3) brogede atrofiske levere (ENG: mottled atrophic livers), (4) mavesår og (5) nefritis, hvor PCV2-ORF2-proteinet er til indgivelse én gang til grise.
2. Immunogen sammensætning ifølge krav 1 til anvendelse ifølge krav 1, hvor det rekombinant fremstillede PCV2-ORF2-protein er baculovirus udtrykt PCV2-ORF2-protein.
3. Immunogen sammensætning ifølge krav 1 eller 2 til anvendelse ifølge krav 1 eller krav 2, hvor det rekombinant fremstillede PCV2-ORF2-protein er blevet tilvejebragt ved en fremgangsmåde, hvor - modtagelige celler inficeres med en rekombinant baculovirusvektor, som indeholder PCV2-ORF2-DNA-kodende sekvenser, - PCV2-ORF2-polypeptid udtrykkes af den rekombinante baculovirus, og - det udtrykte PCV2-ORF2-polypeptid indvindes fra supernatanten ved filtrering og inaktiveres.
4. Immunogen sammensætning ifølge et hvilket som helst af krav 1 til 3 til anvendelse ifølge et hvilket som helst af krav 1 til 3, hvor det rekombinant fremstillede PCV2-ORF2-protein er blevet indvundet fra supernatanten af in vitro-dyrkede celler, hvor cellerne blev inficeret med en rekombinant baculovirus vektor, som indeholder PCV2-ORF2-DNA og udtrykte PCV2-ORF2-protein, og hvor cellekulturen blev behandlet med omkring 2 til omkring 8 mM BEI for at inaktivere baculovirusvektoren, og en ækvivalent koncentration af et neutraliseringsmiddel.
5. Immunogen sammensætning ifølge et hvilket som helst af krav 1 til 4 til anvendelse ifølge et hvilket som helst af krav 1 til 4, yderligere omfattende mindst en del af rekombinant baculovirusvektor, der udtrykker PCV2-ORF2-proteinet.
6. Immunogen sammensætning ifølge krav 5 til anvendelse ifølge krav 5, yderligere omfattende en del af cellekultursupernatant.
7. Immunogen sammensætning ifølge et hvilket som helst af krav 1 til 6 til anvendelse ifølge et hvilket som helst af krav 1 til 6, hvor den immunogene sammensætning er en vaccine.
8. Immunogen sammensætning ifølge et hvilket som helst af krav 1 til 7 til anvendelse ifølge et hvilket som helst af krav 1 til 7, som omfatter fra omkring 0,3 til omkring 200 pg af det rekombinant fremstillede PCV2-ORF2-protein per dosis.
9. Immunogen sammensætning ifølge et hvilket som helst af krav 1 til 8 til anvendelse ifølge et hvilket som helst af krav 1 til 8, hvor grisene er grise der er 2 uger garn- le eller ældre, men ikke ældre end 15 uger gamle.
10. Immunogen sammensætning ifølge et hvilket som helst af krav 1 til 9 til anvendelse ifølge et hvilket som helst af krav 1 til 9, hvor den immunogene sammensætning yderligere omfatter et adjuvans.
11. Immunogen sammensætning ifølge krav 10 til anvendelse ifølge krav 10, hvor adjuvanset kan indbefatte aluminiumhydroxid og aluminiumphosphat, saponiner, vand-i-olie-emulsion, olie-i-vand-emulsion, vand-i-olie-i-vand-emulsion eller, hvor adjuvanset er en forbindelse valgt blandt polymererne af acryl- eller methacrylsyre og copolymererne af maleinanhydrid og alkenylderivat.
12. Immunogen sammensætning ifølge krav 10 eller 11 til anvendelse ifølge krav 10 eller 11, som omfatter 100 pg til 10 mg af adjuvanset per dosis.
13. Immunogen sammensætning ifølge et hvilket som helst af krav 1 til 12 til anvendelse ifølge et hvilket som helst af krav 1 til 12, hvor den immunogene sammensætning er i alt væsentligt fri af antigener eller polypeptider fra PCV2 bortset fra PCV2-ORF2-protein.
14. Immunogen sammensætning ifølge krav 4 til anvendelse ifølge krav 4 og yderligere omfattende et adjuvans anført i krav 11, hvor den immunogene sammensætning er stabil over en periode på 24 måneder.
15. Immunogen sammensætning ifølge et hvilket som helst af krav 1 til 14 til anvendelse ifølge et hvilket som helst af krav 1 til 14, hvor lægemidlet er til indgivelse intra-muskulært.
16. Anvendelse af en immunogen sammensætning i stand til at frembringe eller øge et immunrespons mod PCV2, og som omfatter rekombinant fremstillet PCV2-ORF2-protein til fremstilling af et lægemiddel til forebyggelse af lymfadenopati i kombination med ét eller flere af de følgende symptomer i grise: (1) interstitiel pneumoni med interlobulær ødem, (2) kutan bleghed eller ikterus, (3) brogede atrofiske levere (ENG: mottled atrophic livers), (4) mavesår og (5) nefritis, hvor PCV2-ORF2-proteinet er til indgivelse én gang til grise.
17. Anvendelse ifølge krav 16, hvor det rekombinant fremstillede PCV2-ORF2-protein er baculovirus-udtykt PCV2-ORF2-protein.
18. Anvendelse ifølge krav 16 eller 17, hvor det rekombinant fremstillede PCV2-ORF2-protein er blevet tilvejebragt ved en fremgangsmåde, hvor - modtagelige celler inficeres med en rekombinant baculovirusvektor, som indeholder PCV2-ORF2-DNA-kodende sekvenser, - PCV2-ORF2-polypeptid udtrykkes af den rekombinante baculovirus, og - det udtrykte PCV2-ORF2-polypeptid indvindes fra supernatanten ved filtrering og inaktiveres.
19. Anvendelse ifølge et hvilket som helst af krav 16 til 18, hvor det rekombinant fremstillede PCV2-ORF2-protein er blevet indvundet fra supernatanten af in w'tro-dyrkede celler, hvor cellerne blev inficeret med en rekombinant baculovirus vektor, som indeholder PCV2-ORF2-DNA og udtrykte PCV2-ORF2-protein, og hvor cellekulturen blev behandlet med omkring 2 til omkring 8 mM BEI for at inaktivere baculovirusvektoren, og en ækvivalent koncentration af et neutraliseringsmiddel.
20. Anvendelse ifølge et hvilket som helst af krav 16 til 19, hvor sammensætningen yderligere omfatter mindst en del af rekombinant baculovirusvektor, der udtrykker PCV2-ORF2-protein.
21. Anvendelse ifølge krav 20, hvor sammensætningen yderligere omfattende en del af cellekultursupernatant.
22. Anvendelse ifølge et hvilket som helst af krav 16 til 21, hvor den immunogene sammensætning er en vaccine.
23. Anvendelse ifølge et hvilket som helst af krav 16 til 22, hvor sammensætningen omfattende fra omkring 0,3 til omkring 200 pg af det rekombinant fremstillede PCV2-ORF2-protein per dosis.
24. Anvendelse ifølge et hvilket som helst af krav 16 til 23, hvor grisene er grise, der er 2 uger gamle eller ældre, men ikke ældre end 15 uger gamle.
25. Anvendelse ifølge et hvilket som helst af krav 16 til 24, hvor den immunogene sammensætning yderligere omfatter et adjuvans.
26. Anvendelse ifølge krav 25, hvor adjuvanset kan indbefatte aluminiumhydroxid og aluminiumphosphat, saponiner, vand-i-olie-emulsion, olie-i-vand-emulsion, vand-i-olie-i-vand-emulsion eller, hvor adjuvanset er en forbindelse valgt blandt polymererne af acryl- eller methacrylsyre og copolymererne af maleinanhydrid og alkenylderivat.
27. Anvendelse ifølge krav 25 eller 26, hvor sammensætningen omfatter 100 pg til 10 mg af adjuvans per dosis.
28. Anvendelse ifølge et hvilket som helst af krav 16 til 27, hvor den immunogene sammensætning er i alt væsentligt fri af antigener eller polypeptider fra PCV2 bortset fra PCV2-ORF2-protein.
29. Anvendelse ifølge krav 19, hvor den immunogene sammensætning yderligere omfatter et adjuvans anført i krav 26 og er stabil over en periode på 24 måneder.
30. Anvendelse ifølge et hvilket som helst af krav 16 til 29, hvor lægemidlet er til indgivelse intramuskulært.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75501605P | 2005-12-29 | 2005-12-29 | |
US82980906P | 2006-10-17 | 2006-10-17 | |
EP06850366.3A EP1976558B1 (en) | 2005-12-29 | 2006-12-28 | Pcv2 immunogenic composition for lessening clinical symptoms in pigs |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2371385T3 true DK2371385T3 (da) | 2015-11-30 |
Family
ID=38371964
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11164850.7T DK2371383T3 (da) | 2005-12-29 | 2006-12-28 | Anvendelse af en PCV2-immunogen sammensætning til mindskning af kliniske symptomer i grise |
DK11164854.9T DK2371385T3 (da) | 2005-12-29 | 2006-12-28 | Anvendelse af en PV2-immunogen sammensætning til mindskning af kliniske symptomer i grise |
DK16185663.8T DK3127551T3 (da) | 2005-12-29 | 2006-12-28 | Pcv2-immunogen-sammensætning til at mindske kliniske symptomer i grise |
DK11164849.9T DK2371382T3 (da) | 2005-12-29 | 2006-12-28 | Anvendelse af en PCV2-immunogen sammensætning til at mindske kliniske symptomer hos svin |
DK06850366.3T DK1976558T3 (da) | 2005-12-29 | 2006-12-28 | Pcv2-immunogen sammensætning til at mindske kliniske symptomer i grise. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11164850.7T DK2371383T3 (da) | 2005-12-29 | 2006-12-28 | Anvendelse af en PCV2-immunogen sammensætning til mindskning af kliniske symptomer i grise |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16185663.8T DK3127551T3 (da) | 2005-12-29 | 2006-12-28 | Pcv2-immunogen-sammensætning til at mindske kliniske symptomer i grise |
DK11164849.9T DK2371382T3 (da) | 2005-12-29 | 2006-12-28 | Anvendelse af en PCV2-immunogen sammensætning til at mindske kliniske symptomer hos svin |
DK06850366.3T DK1976558T3 (da) | 2005-12-29 | 2006-12-28 | Pcv2-immunogen sammensætning til at mindske kliniske symptomer i grise. |
Country Status (18)
Country | Link |
---|---|
US (12) | US20080181910A1 (da) |
EP (11) | EP3127551B1 (da) |
JP (2) | JP5739602B2 (da) |
KR (2) | KR20140019479A (da) |
CN (4) | CN104383526B (da) |
AR (1) | AR058871A1 (da) |
AU (1) | AU2006338182B2 (da) |
BR (1) | BRPI0620823B1 (da) |
CA (1) | CA2635430A1 (da) |
DK (5) | DK2371383T3 (da) |
ES (5) | ES2553253T3 (da) |
HU (4) | HUE029552T2 (da) |
MX (4) | MX356667B (da) |
PL (4) | PL2371383T3 (da) |
PT (3) | PT2371385E (da) |
SG (1) | SG170792A1 (da) |
TW (1) | TW200800256A (da) |
WO (1) | WO2007094893A2 (da) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2772047B1 (fr) * | 1997-12-05 | 2004-04-09 | Ct Nat D Etudes Veterinaires E | Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection |
UA95602C2 (ru) | 2004-12-30 | 2011-08-25 | Берингер Ингельхейм Ветмедика, Инк. | Иммуногенная композиция цвс2 и способы приготовления такой композиции |
US7700285B1 (en) | 2005-12-29 | 2010-04-20 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
US7833707B2 (en) | 2004-12-30 | 2010-11-16 | Boehringer Ingelheim Vetmedica, Inc. | Methods of overexpression and recovery of porcine circovirus type 2 ORF2 |
US8834891B2 (en) | 2005-03-14 | 2014-09-16 | Boehringer Ingelheim Vetmedica, Inc. | Immunogenic compositions comprising Lawsonia intracellularis |
HUE054868T2 (hu) * | 2005-12-29 | 2021-10-28 | Boehringer Ingelheim Animal Health Usa Inc | Multivalens PVC2 immunogén készítmények és eljárások ezek elõállítására |
DK2371383T3 (da) | 2005-12-29 | 2015-11-30 | Boehringer Ingelheim Vetmed | Anvendelse af en PCV2-immunogen sammensætning til mindskning af kliniske symptomer i grise |
WO2008064299A2 (en) * | 2006-11-22 | 2008-05-29 | Boehringer Ingelheim Vetmedica, Inc. | Methods of reducing porcine circovirus-associated disease outbreaks |
US20100129397A1 (en) * | 2006-12-11 | 2010-05-27 | Boehringer Ingelheim Vetmedica, Inc. | Effective method of treatment of porcine circovirus and lawsonia intracellularis infections |
RU2520087C2 (ru) * | 2006-12-15 | 2014-06-20 | Бёрингер Ингельхайм Ветмедика, Инк. | Лечение свиней с помощью антигена pcv2 |
EP1941903A1 (en) * | 2007-01-03 | 2008-07-09 | Boehringer Ingelheim Vetmedica Gmbh | Prophylaxis and treatment of PRDC |
EP1958644A1 (en) | 2007-02-13 | 2008-08-20 | Boehringer Ingelheim Vetmedica Gmbh | Prevention and treatment of sub-clinical pcvd |
US7829274B2 (en) * | 2007-09-04 | 2010-11-09 | Boehringer Ingelheim Vetmedica, Inc. | Reduction of concomitant infections in pigs by the use of PCV2 antigen |
JP2011507522A (ja) * | 2007-12-21 | 2011-03-10 | ワイス・エルエルシー | 豚サーコウイルスに対してブタを免疫化するための方法および組成物 |
EP2231182A4 (en) * | 2007-12-31 | 2012-08-22 | Boehringer Ingelheim Vetmed | PCV2-ORF2-VIRUSELY PARTICLES WITH FREMDAMINO-ACID INSERTION |
US20090317423A1 (en) | 2008-01-23 | 2009-12-24 | Boehringer Ingelheim Vetmedica, Inc. | Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions |
WO2009103037A1 (en) * | 2008-02-15 | 2009-08-20 | Boehringer Ingelheim Vetmedica, Inc. | Methods and compositions for reducing the impact of enteric diseases |
TWI449533B (zh) | 2008-04-18 | 2014-08-21 | Intervet Int Bv | 防備胞內勞森菌(Lawsonia intracellularis)、豬肺炎黴漿菌(Mycoplasma hyopneumoniae)及豬環狀病毒(Porcine circo virus)用疫苗 |
TWI627281B (zh) | 2009-09-02 | 2018-06-21 | 百靈佳殷格翰家畜藥品公司 | 降低pcv-2組合物殺病毒活性之方法及具有改良免疫原性之pcv-2組合物 |
CN103108653B (zh) | 2010-07-08 | 2015-07-22 | 美国联合生物医学公司 | 设计肽的pcv2疫苗 |
TWI442935B (zh) | 2010-12-22 | 2014-07-01 | Sbc Virbac Ltd | 豬第二型環狀病毒(Porcine Circovirus Type 2)、含彼之免疫組合物、檢測套組及其應用 |
UA114503C2 (uk) * | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv та mycoplasma hyopneumoniae |
WO2015048115A1 (en) | 2013-09-25 | 2015-04-02 | Zoetis Llc | Pcv2b divergent vaccine composition and methods of use |
EA035265B1 (ru) | 2013-10-02 | 2020-05-21 | Бёрингер Ингельхайм Энимал Хелс Ю-Эс-Эй Инк. | Вариант белка opc2 pcv2 и содержащие его вирусоподобные частицы |
RU2712155C2 (ru) | 2013-12-03 | 2020-01-24 | Интервет Интернэшнл Б.В. | Вакцина против цирковируса свиней 2 типа |
CA2931136C (en) | 2013-12-03 | 2023-03-21 | Intervet International B.V. | Vaccine against lawsonia intracellularis and porcine circovirus 2 |
BR112018007525A2 (pt) * | 2015-10-16 | 2018-10-30 | Kansas State University Research Foundation | composições imunogênicas de circovírus suíno tipo 3 e métodos de produzir e usar as mesmas |
RU2701816C1 (ru) * | 2015-12-28 | 2019-10-01 | Эгрикалчурал Текнолоджи Рисерч Инститьют | Способ получения капсидного белка цирковируса свиней 2 типа и содержащая его фармацевтическая композиция |
JP2019512518A (ja) | 2016-03-23 | 2019-05-16 | インターベット インターナショナル ベー. フェー. | Pcv2およびprrsウイルス感染に対する皮内適用のためのワクチン |
WO2017162741A1 (en) | 2016-03-23 | 2017-09-28 | Intervet International B.V. | A combination vaccine against pcv2 virus and mycoplasma hyopneumoniae infection |
JP2019509302A (ja) | 2016-03-23 | 2019-04-04 | インターベット インターナショナル ベー. フェー. | アルブミンを含むpcv2及びprrsウイルス感染症に対する混合ワクチン |
US11622872B2 (en) | 2016-05-16 | 2023-04-11 | Elixir Medical Corporation | Uncaging stent |
CN109561955B (zh) | 2016-05-16 | 2021-04-16 | 万能医药公司 | 撑开支架 |
MY191895A (en) | 2016-11-03 | 2022-07-18 | Boehringer Ingelheim Vetmedica Gmbh | Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof |
EP4335455A2 (en) | 2017-04-13 | 2024-03-13 | Intervet International B.V. | Vaccines containing swine pathogens for associated non-mixed use |
CN109010818B (zh) * | 2017-06-09 | 2021-11-09 | 普莱柯生物工程股份有限公司 | 一种预防和/或治疗猪圆环病毒感染的二联疫苗组合物及其制备方法和应用 |
US11077181B2 (en) | 2017-08-03 | 2021-08-03 | Intervet Inc. | Vaccine comprising a PCV2 ORF2 protein of genotype 2b |
CN112773583B (zh) | 2017-08-11 | 2024-01-09 | 万能医药公司 | 撑开支架 |
TWI762706B (zh) | 2017-08-24 | 2022-05-01 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1組成物及其用途 |
JP7162072B2 (ja) | 2018-03-26 | 2022-10-27 | ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド | 免疫原性組成物を製造する方法 |
CN114222579A (zh) | 2019-04-04 | 2022-03-22 | 勃林格殷格翰动物保健美国有限公司 | 猪圆环病毒3型(pcv3)疫苗及其生产和用途 |
WO2021048338A1 (en) | 2019-09-12 | 2021-03-18 | Intervet International B.V. | Combination vaccine for intradermal administration |
WO2021144476A1 (en) | 2020-02-18 | 2021-07-22 | Novo Nordisk A/S | Pharmaceutical formulations |
FR3107454B1 (fr) | 2020-02-20 | 2023-02-10 | Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic | Adjuvant de vaccin comprenant un microlatex inverse |
US20230338500A1 (en) | 2020-04-20 | 2023-10-26 | Intervet Inc. | A combination of vaccines to prophylactically treat a pig |
US20230241198A1 (en) | 2020-07-24 | 2023-08-03 | Boehringer Ingelheim Animal Health USA Inc. | Combination porcine vaccine |
EP4236998A1 (en) | 2020-10-29 | 2023-09-06 | Intervet International B.V. | Combination vaccine for protecting swine against various disorders |
Family Cites Families (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US755016A (en) | 1903-06-08 | 1904-03-22 | Charles Herschel Koyl | Coal-separating apparatus. |
US829809A (en) | 1906-04-10 | 1906-08-28 | Arthur H Swan | Peel-blade tip. |
US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
US3479705A (en) | 1966-12-15 | 1969-11-25 | Miami Brick & Stone Inc Of Mia | Molding apparatus |
NL7903764A (nl) | 1979-05-14 | 1980-11-18 | Shell Int Research | Werkwijze ter bereiding van calcium-houdend lood, daarmee verkregen lood en daaruit verkregen accuplaten of -roosters. |
JPS60500673A (ja) | 1983-03-08 | 1985-05-09 | コモンウエルス セラム ラボラトリ−ズ コミツシヨン | 抗原活性を有するアミノ酸配列 |
EP0283085B1 (en) | 1987-03-17 | 1992-11-11 | Akzo N.V. | Adjuvant mixture |
US5069901A (en) | 1988-02-03 | 1991-12-03 | Jones Elaine V | Preparation of a recombinant subunit vaccine against pseudorabies infection |
DK0454735T3 (da) | 1989-01-23 | 1996-10-07 | Auspharm Int Ltd | Vaccine sammensætning |
US5155037A (en) | 1989-08-04 | 1992-10-13 | The Texas A&M University System | Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems |
US5202430A (en) | 1990-01-16 | 1993-04-13 | University Of Tennessee | Transmissible gastroenteritis virus genes |
EP0597852B2 (en) | 1990-05-29 | 2005-08-10 | Wyeth Holdings Corporation | Swine pneumonia vaccine and method for the preparation thereof |
JP3046332B2 (ja) * | 1990-08-02 | 2000-05-29 | 協和醗酵工業株式会社 | 発酵法によるアミノ酸の製造法 |
US5565205A (en) | 1990-08-16 | 1996-10-15 | Solvay Animal Health, Inc. | Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof |
NL9301272A (nl) | 1993-07-20 | 1995-02-16 | Aesculaap Bv | Chicken Anemia Virus mutanten en vaccins en toepassingen gebaseerd op de virale eiwitten VP1, VP2 en VP3 of daarvoor coderende sequenties van dat virus. |
GB9023111D0 (en) | 1990-10-24 | 1990-12-05 | Wellcome Found | Expression system |
ES2150419T3 (es) | 1990-11-01 | 2000-12-01 | Univ Iowa State Res Found Inc | Procedimiento de atenuacion bacteriana y vacuna. |
US6042830A (en) | 1992-08-05 | 2000-03-28 | Boehringer Ingelheim Vetmedica, Inc. | Viral agent associated with mystery swine disease |
KR0138092B1 (ko) | 1991-08-26 | 1998-04-30 | 제임스 씨. 데세사레 | 미확인(Mystery) 돼지 질병 관련 바이러스제 |
US5580557A (en) * | 1991-10-09 | 1996-12-03 | Iowa State University Research Foundation, Inc. | Live, avirulent salmonella choleraesuis vaccine used for inducing an immune response in animals |
US5338543A (en) | 1992-02-27 | 1994-08-16 | Ambico, Inc. | Thimerosal inactivated mycoplasma hyopneumoniae vaccine |
CN1070078C (zh) * | 1993-11-24 | 2001-08-29 | 中国农科院兰州兽医研究所 | 口蹄疫疫苗的生产工艺 |
DE69535520T2 (de) | 1994-05-10 | 2008-02-07 | Wyeth | Abgeänderter, verbesserter BRSV Lebend- Impfstoff |
US5885823A (en) | 1995-06-05 | 1999-03-23 | Nobl Laboratories, Inc. | Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents |
WO1998006855A1 (en) | 1996-08-16 | 1998-02-19 | The Texas A & M University System | Compositions and methods for delivery of nucleic acids to hepatocytes |
ATE199022T1 (de) | 1996-10-09 | 2001-02-15 | Akzo Nobel Nv | Europäische vakzinstämme des fortplanzungs- atmungs-syndromsvirus des sweins (prrsv) |
US7211379B2 (en) * | 1997-10-03 | 2007-05-01 | Merial Sas | Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2 |
UA78180C2 (uk) | 1997-10-03 | 2007-03-15 | Меріаль | Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти |
US6391314B1 (en) | 1997-10-03 | 2002-05-21 | Merial | Porcine circoviruses vaccines diagnostic reagents |
US6517843B1 (en) | 1999-08-31 | 2003-02-11 | Merial | Reduction of porcine circovirus-2 viral load with inactivated PCV-2 |
AU2002302120B2 (en) * | 1997-10-03 | 2006-01-19 | Merial | Porcine circoviruses, vaccines and diagnostic reagents |
US7192594B2 (en) | 1997-10-03 | 2007-03-20 | Merial Limited | Postweaning multisystemic wasting syndrome and porcine circovirus from pigs |
US20060029617A1 (en) | 1997-10-03 | 2006-02-09 | Charreyre Catherine E | Porcine circovirus and Helicobacter combination vaccines and methods of use |
FR2781159B1 (fr) | 1998-07-06 | 2000-10-06 | Merial Sas | Vaccin circovirus et parvovirus porcin |
US20040062775A1 (en) | 1997-12-05 | 2004-04-01 | Agence Francaise De Securite Sanitaire Des Aliments | Circovirus sequences associated with piglet weight loss disease (PWD) |
FR2772047B1 (fr) | 1997-12-05 | 2004-04-09 | Ct Nat D Etudes Veterinaires E | Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection |
DK2363488T3 (da) * | 1997-12-11 | 2014-11-24 | Merial Sas | Postweaning multisystemisk wasting syndrom-virus fra grise |
WO1999045956A1 (en) | 1998-03-13 | 1999-09-16 | University Of Georgia Research Foundation, Inc. | Vaccines against circovirus infections |
US6294176B1 (en) | 1998-07-10 | 2001-09-25 | Schering-Plough Veterinary Corp. | Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species |
DE19836659A1 (de) | 1998-08-13 | 2000-02-17 | Hoechst Schering Agrevo Gmbh | Herbizide Mittel für tolerante oder resistente Baumwollkulturen |
WO2000031275A1 (fr) | 1998-11-19 | 2000-06-02 | Azwell Inc. | Phosphatase de recombinaison d'acide lysophosphatidique |
FR2789695B1 (fr) * | 1999-02-11 | 2003-03-07 | Merial Sas | Vecteurs et vaccins viraux a base d'adenovirus porcins recombines et replicatifs |
US6497883B1 (en) * | 1999-06-10 | 2002-12-24 | Merial | Porcine circovirus recombinant poxvirus vaccine |
US6943152B1 (en) | 1999-06-10 | 2005-09-13 | Merial | DNA vaccine-PCV |
WO2001017556A1 (fr) | 1999-09-07 | 2001-03-15 | Shionogi & Co., Ltd. | Préparations vaccinales administrables par les muqueuses |
GB9921146D0 (en) | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
GB9921147D0 (en) | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
US6656478B1 (en) | 1999-11-12 | 2003-12-02 | Samuel D. Charles | Cross-protective salmonella vaccines |
DE60038048T2 (de) | 1999-12-21 | 2009-07-09 | Merial | Mindestens ein cryptosporidium parvum-antigen und mindestens ein antigen eines anderen darmkrankheitserregers enthaltende zusammensetzungen und impfstoffe |
US6808900B2 (en) | 2000-06-15 | 2004-10-26 | Manitoba, University Of | Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof |
EP1290016A2 (en) | 2000-06-15 | 2003-03-12 | Purdue Research Foundation | Vaccine for congenital tremors in pigs |
MY129765A (en) | 2000-12-19 | 2007-04-30 | Wyeth Corp | Improved mycoplasma hyopneumoniae bacterin vaccine |
US7018638B2 (en) | 2000-12-19 | 2006-03-28 | Wyeth | Mycoplasma hyopneumoniae bacterin vaccine |
JP2002247979A (ja) | 2001-02-23 | 2002-09-03 | Nippon Biologicals Inc | マレック病ワクチンおよびその製造方法 |
ES2324466T3 (es) | 2001-03-27 | 2009-08-07 | University Of Saskatchewan | Metodos para cultivar circovirus. |
US20030096377A1 (en) * | 2001-06-28 | 2003-05-22 | Virginia Tech Intellectual Properties, Inc. | Differential PCR-RFLP assay for detecting and distinguishing between nonpathogenic PCV-1 and pathogenic PCV-2 |
ATE412426T2 (de) | 2001-07-02 | 2008-11-15 | Pfizer Prod Inc | Vakzination in einer dosis mit i mycoplasma hyopneumoniae /i |
US7361352B2 (en) | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
US7279166B2 (en) | 2001-12-12 | 2007-10-09 | Virginia Tech Intellectual Properties, Inc. | Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof |
US7276353B2 (en) * | 2001-12-12 | 2007-10-02 | Virginia Tech Intellectual Properties, Inc. | Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof |
US6841364B2 (en) | 2002-01-22 | 2005-01-11 | Protatek International, Inc. | Infectious cDNA clones of porcine reproductive and respiratory syndrome virus and expression vectors thereof |
US20040063188A1 (en) | 2002-02-14 | 2004-04-01 | Novavax, Inc. | Kit for treating gastrointestinal tract |
US20030199581A1 (en) | 2002-03-13 | 2003-10-23 | Seligson Allen L. | Boswellin compositions enhanced with 3-beta-acetyl-11-keto-beta-boswellic acid ("AKBA") industrial manufacture and uses |
US20030215455A1 (en) * | 2002-05-14 | 2003-11-20 | Bailey Reynolds | Vaccine stabilizer and method of use |
US7194472B2 (en) * | 2002-07-05 | 2007-03-20 | Sun Microsystems Inc. | Extending role scope in a directory server system |
US7335362B2 (en) * | 2002-07-19 | 2008-02-26 | Beth Israel Deaconess Medical Center | Methods of treating pre-eclampsia or eclampsia |
US7223207B1 (en) | 2002-09-13 | 2007-05-29 | Simon Basyuk | Exercise and massage device |
AU2002951692A0 (en) | 2002-09-23 | 2002-10-17 | Vital Biotech (Hong Kong) Limited | Improvements in or relating to vaccines |
UA84284C2 (ru) | 2003-02-03 | 2008-10-10 | Сирибас Байолоджикалз, Инк. | Способы лечения, профилактики и диагностики инфекции helicobacter cerdo |
US7563449B2 (en) | 2003-04-21 | 2009-07-21 | Pfizer Inc, | Methods for reducing cattle reproductive diseases |
CN1458167A (zh) | 2003-06-02 | 2003-11-26 | 中国农业科学院哈尔滨兽医研究所 | 截短表达的猪圆环病毒ⅱ型衣壳蛋白抗原及其应用 |
US7335361B2 (en) | 2003-06-09 | 2008-02-26 | Animal Technology Institute Taiwan | Fusion antigen used as vaccine |
NO321276B1 (no) | 2003-07-07 | 2006-04-18 | Elkem Materials | Fremgangsmate for fremstilling av triklorsilan og silisium for bruk ved fremstilling av triklorsilan |
MXPA06000942A (es) | 2003-07-24 | 2006-03-30 | Merial Ltd | Nuevas formulaciones de vacunas. |
ES2333334T5 (es) | 2003-07-25 | 2018-08-06 | Boehringer Ingelheim Vetmedica, Inc. | Lawsonia intracellularis de origen europeo y vacunas, agentes de diagnóstico y métodos de uso de la misma |
FR2861731B1 (fr) | 2003-10-30 | 2006-02-24 | Centre Nat Rech Scient | Nouvelle proteine de fixation du phosphate, compositions pharmaceutiques la contenant et ses utilisations |
WO2005112995A1 (en) | 2004-04-26 | 2005-12-01 | Choongang Vaccine Laboratory Co., Ltd. | Inactivated mixed vaccine for porcine respiratory disease and the method of manufacturing thereof |
CN1579553A (zh) * | 2004-05-18 | 2005-02-16 | 浙江大学 | Ii型猪圆环病毒核酸疫苗的制备方法及其应用 |
KR100478845B1 (ko) | 2004-06-22 | 2005-03-24 | 채찬희 | 돼지 이유자돈 전신성 소모성 증후군 예방 및 치료용 생물학적 조성물 |
KR20070052273A (ko) | 2004-06-30 | 2007-05-21 | 아이디 바이오메디컬 코포레이션 오브 퀘벡 | 코로나바이러스 감염의 치료를 위한 백신 조성물 |
US7258075B1 (en) * | 2004-08-13 | 2007-08-21 | World Factory, Inc. | Collapsible bird feeder |
US7700285B1 (en) | 2005-12-29 | 2010-04-20 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
UA95602C2 (ru) | 2004-12-30 | 2011-08-25 | Берингер Ингельхейм Ветмедика, Инк. | Иммуногенная композиция цвс2 и способы приготовления такой композиции |
US7833707B2 (en) * | 2004-12-30 | 2010-11-16 | Boehringer Ingelheim Vetmedica, Inc. | Methods of overexpression and recovery of porcine circovirus type 2 ORF2 |
KR20070096019A (ko) | 2005-01-13 | 2007-10-01 | 베링거잉겔하임베트메디카게엠베하 | 향상된 prrs 백신 |
US7300785B2 (en) | 2005-02-03 | 2007-11-27 | Universiteit Ghent | Culturing circular ssDNA viruses for the production of vaccines |
US8834891B2 (en) | 2005-03-14 | 2014-09-16 | Boehringer Ingelheim Vetmedica, Inc. | Immunogenic compositions comprising Lawsonia intracellularis |
PT1869471T (pt) | 2005-04-13 | 2016-08-16 | Merial Inc | Ensaio para a produção de circovírus suíno |
US7691368B2 (en) * | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
BRPI0615862A2 (pt) * | 2005-09-09 | 2011-05-31 | Intervet Int Bv | vacina contra pcv-2, e, método para a manufatura de uma vacina |
DK2371383T3 (da) | 2005-12-29 | 2015-11-30 | Boehringer Ingelheim Vetmed | Anvendelse af en PCV2-immunogen sammensætning til mindskning af kliniske symptomer i grise |
HUE054868T2 (hu) | 2005-12-29 | 2021-10-28 | Boehringer Ingelheim Animal Health Usa Inc | Multivalens PVC2 immunogén készítmények és eljárások ezek elõállítására |
WO2007094983A2 (en) | 2006-02-03 | 2007-08-23 | Tanox, Inc. | Methods and compositions for the inhibition of hiv infection of t cells |
WO2008064299A2 (en) | 2006-11-22 | 2008-05-29 | Boehringer Ingelheim Vetmedica, Inc. | Methods of reducing porcine circovirus-associated disease outbreaks |
US20100129397A1 (en) | 2006-12-11 | 2010-05-27 | Boehringer Ingelheim Vetmedica, Inc. | Effective method of treatment of porcine circovirus and lawsonia intracellularis infections |
RU2520087C2 (ru) | 2006-12-15 | 2014-06-20 | Бёрингер Ингельхайм Ветмедика, Инк. | Лечение свиней с помощью антигена pcv2 |
EP1941903A1 (en) * | 2007-01-03 | 2008-07-09 | Boehringer Ingelheim Vetmedica Gmbh | Prophylaxis and treatment of PRDC |
EP1958644A1 (en) | 2007-02-13 | 2008-08-20 | Boehringer Ingelheim Vetmedica Gmbh | Prevention and treatment of sub-clinical pcvd |
GB0712160D0 (en) | 2007-06-22 | 2007-08-01 | Univ Ghent | Methods and compositions in the treatment of procine circoviral infection |
US20090017064A1 (en) | 2007-07-10 | 2009-01-15 | Wyeth | Methods and Compositions for Immunizing Pigs Against Porcine Circovirus |
US7829274B2 (en) | 2007-09-04 | 2010-11-09 | Boehringer Ingelheim Vetmedica, Inc. | Reduction of concomitant infections in pigs by the use of PCV2 antigen |
US20090317423A1 (en) | 2008-01-23 | 2009-12-24 | Boehringer Ingelheim Vetmedica, Inc. | Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions |
WO2009103037A1 (en) | 2008-02-15 | 2009-08-20 | Boehringer Ingelheim Vetmedica, Inc. | Methods and compositions for reducing the impact of enteric diseases |
US8444989B1 (en) | 2008-04-18 | 2013-05-21 | Boehringer Ingelheim Vetmedica Gmbh | One dose vaccination against mycoplasma infections of pigs |
US20100150959A1 (en) | 2008-12-15 | 2010-06-17 | Vectogen Pty Ltd. | PCV 2-Based Methods and Compositions for the Treatment of Pigs |
TWI627281B (zh) | 2009-09-02 | 2018-06-21 | 百靈佳殷格翰家畜藥品公司 | 降低pcv-2組合物殺病毒活性之方法及具有改良免疫原性之pcv-2組合物 |
US20110150770A1 (en) | 2009-12-18 | 2011-06-23 | Boehringer Ingelheim Vetmedica, Inc. | Multivalent vaccine against porcine teschovirus and other disease causing organisms in swine |
PL2547770T3 (pl) | 2010-03-16 | 2020-06-29 | Virginia Tech Intellectual Properties, Inc. | Szczepionka zawierająca żywy atenuowany chimeryczny cirkowirus świń |
WO2012033911A2 (en) | 2010-09-08 | 2012-03-15 | The Johns Hopkins University | Polyionic papilloma virus-like particle (vlp) vaccines |
CN103122352B (zh) | 2012-09-27 | 2015-02-11 | 华中农业大学 | 一种猪圆环病毒2型重组杆状病毒及制备方法和应用 |
ES2734374T3 (es) | 2013-03-01 | 2019-12-05 | Boehringer Ingelheim Animal Health Usa Inc | Cuantificación de composiciones de vacuna |
EP2991676A1 (en) | 2013-04-30 | 2016-03-09 | Boehringer Ingelheim Vetmedica, Inc. | Orf2 protein of pcv2 subtype a (pcv2a) for use in cross-protection |
WO2014187822A1 (en) | 2013-05-22 | 2014-11-27 | Boehringer Ingelheim Espana, S.A. | Method for the reduction of pcv-2 in a herd of swine |
WO2015026912A1 (en) | 2013-08-23 | 2015-02-26 | Boehringer Ingelheim Vetmedica, Inc. | Porcine circovirus type 2 (pcv2) subunit vaccine |
EA035265B1 (ru) | 2013-10-02 | 2020-05-21 | Бёрингер Ингельхайм Энимал Хелс Ю-Эс-Эй Инк. | Вариант белка opc2 pcv2 и содержащие его вирусоподобные частицы |
JP6580070B2 (ja) | 2014-05-07 | 2019-09-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 容器、ネブライザ、及び使用 |
CN107531760A (zh) | 2015-03-30 | 2018-01-02 | 勃林格殷格翰动物保健公司 | Pcv2 orf2载体平台 |
-
2006
- 2006-12-28 DK DK11164850.7T patent/DK2371383T3/da active
- 2006-12-28 SG SG201102211-8A patent/SG170792A1/en unknown
- 2006-12-28 EP EP16185663.8A patent/EP3127551B1/en active Active
- 2006-12-28 WO PCT/US2006/062662 patent/WO2007094893A2/en active Application Filing
- 2006-12-28 EP EP20184598.9A patent/EP3766518A1/en active Pending
- 2006-12-28 HU HUE11164849A patent/HUE029552T2/en unknown
- 2006-12-28 CN CN201410534903.8A patent/CN104383526B/zh active Active
- 2006-12-28 DK DK11164854.9T patent/DK2371385T3/da active
- 2006-12-28 CA CA002635430A patent/CA2635430A1/en not_active Abandoned
- 2006-12-28 PT PT111648549T patent/PT2371385E/pt unknown
- 2006-12-28 KR KR1020147001544A patent/KR20140019479A/ko active Search and Examination
- 2006-12-28 JP JP2008548847A patent/JP5739602B2/ja active Active
- 2006-12-28 HU HUE16185663A patent/HUE051784T2/hu unknown
- 2006-12-28 EP EP11164854.9A patent/EP2371385B1/en not_active Revoked
- 2006-12-28 PL PL11164850T patent/PL2371383T3/pl unknown
- 2006-12-28 BR BRPI0620823A patent/BRPI0620823B1/pt active IP Right Grant
- 2006-12-28 HU HUE11164854A patent/HUE025994T2/en unknown
- 2006-12-28 HU HUE11164850A patent/HUE026205T2/en unknown
- 2006-12-28 TW TW095149552A patent/TW200800256A/zh unknown
- 2006-12-28 PT PT111648507T patent/PT2371383E/pt unknown
- 2006-12-28 CN CN200680053578.7A patent/CN101426522B/zh active Active
- 2006-12-28 ES ES11164850.7T patent/ES2553253T3/es active Active
- 2006-12-28 ES ES11164854.9T patent/ES2553254T3/es active Active
- 2006-12-28 EP EP11164852A patent/EP2371384A1/en not_active Withdrawn
- 2006-12-28 ES ES06850366.3T patent/ES2625903T3/es active Active
- 2006-12-28 ES ES11164849.9T patent/ES2572736T3/es active Active
- 2006-12-28 MX MX2016013804A patent/MX356667B/es unknown
- 2006-12-28 EP EP11164849.9A patent/EP2371382B1/en not_active Revoked
- 2006-12-28 CN CN201410534901.9A patent/CN104474541B/zh active Active
- 2006-12-28 US US11/617,435 patent/US20080181910A1/en not_active Abandoned
- 2006-12-28 PL PL11164849T patent/PL2371382T3/pl unknown
- 2006-12-28 KR KR1020087018597A patent/KR20080093112A/ko active Search and Examination
- 2006-12-28 CN CN201811123454.2A patent/CN109125721A/zh active Pending
- 2006-12-28 MX MX2013012700A patent/MX338626B/es unknown
- 2006-12-28 EP EP11164850.7A patent/EP2371383B1/en not_active Revoked
- 2006-12-28 EP EP10174456A patent/EP2275130A3/en not_active Withdrawn
- 2006-12-28 DK DK16185663.8T patent/DK3127551T3/da active
- 2006-12-28 DK DK11164849.9T patent/DK2371382T3/da active
- 2006-12-28 EP EP11164856A patent/EP2374476A1/en not_active Withdrawn
- 2006-12-28 MX MX2008008311A patent/MX2008008311A/es active IP Right Grant
- 2006-12-28 EP EP11164858A patent/EP2371386A1/en not_active Withdrawn
- 2006-12-28 PL PL11164854T patent/PL2371385T3/pl unknown
- 2006-12-28 ES ES16185663T patent/ES2824113T3/es active Active
- 2006-12-28 EP EP11164855A patent/EP2374475A1/en not_active Withdrawn
- 2006-12-28 AR ARP060105837A patent/AR058871A1/es not_active Withdrawn
- 2006-12-28 AU AU2006338182A patent/AU2006338182B2/en active Active
- 2006-12-28 PL PL16185663T patent/PL3127551T3/pl unknown
- 2006-12-28 PT PT161856638T patent/PT3127551T/pt unknown
- 2006-12-28 MX MX2012007937A patent/MX343001B/es unknown
- 2006-12-28 EP EP06850366.3A patent/EP1976558B1/en not_active Revoked
- 2006-12-28 DK DK06850366.3T patent/DK1976558T3/da active
-
2008
- 2008-06-11 US US12/137,086 patent/US20080267995A1/en not_active Abandoned
- 2008-06-11 US US12/137,105 patent/US20080279889A1/en not_active Abandoned
- 2008-06-11 US US12/137,141 patent/US7829273B2/en active Active
- 2008-06-11 US US12/136,923 patent/US7968285B2/en active Active
- 2008-06-11 US US12/136,942 patent/US7838213B2/en active Active
- 2008-06-11 US US12/137,067 patent/US7838214B2/en active Active
-
2011
- 2011-05-12 US US13/106,606 patent/US9011868B2/en active Active
-
2013
- 2013-01-04 JP JP2013000182A patent/JP2013067655A/ja active Pending
-
2015
- 2015-03-18 US US14/661,969 patent/US9669087B2/en active Active
-
2016
- 2016-03-21 US US15/076,381 patent/US9987349B2/en active Active
- 2016-08-26 US US15/249,158 patent/US9610345B2/en active Active
-
2018
- 2018-04-19 US US15/957,663 patent/US10568955B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2371385T3 (da) | Anvendelse af en PV2-immunogen sammensætning til mindskning af kliniske symptomer i grise | |
DK2460817T3 (da) | Immunogene PCV2-sammensætninger og fremgangsmåder til fremstilling af sådanne sammensætninger | |
CA2670836C (en) | Treatment of pigs with pcv2 antigen | |
DK2481421T3 (da) | Behandling af subklinisk PCVD | |
AU2009234345B2 (en) | PCV2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions | |
DK1968630T5 (da) | Multivalente pcv2-immunogeniske sammensætninger. | |
CA2698301C (en) | Reduction of concomitant infections in pigs by the use of pcv2 antigen | |
KR20090099005A (ko) | 돼지의 prdc 치료 | |
HUE025537T2 (en) | PCV2-immunogenic compositions and methods for preparing such compositions |